ERBB2 and breast carcinoma: Recent evidence further underscores the biological heterogeneity of HER2-negative tumors in men, with reports identifying both a distinct HER2-low subgroup [18] and considerable variation in HER2 pathway activation across large male cohorts [19], findings that are consistent with our observation that HER2 status represents an important prognostic and potentially therapeutic determinant in male breast cancer.